@joshua/heart-failure-and-af-anticoagulation
Heart failure and AF anticoagulation
Author-made · not reviewedCardiologyCC BY 4.0
Written by the BenchClub team with AI help. Answers follow public guidelines and textbooks; not yet reviewed by a practising physician.
v128 questionsUpdated Nov 17, 2026
- HF-001Multiple choiceCardiologyBasic
A 62-year-old man had an anterior MI 3 years ago and has had exertional dyspnea for 2 months (NYHA class II). Echocardiography shows LVEF 30%. His only medication is furosemide 20 mg daily. He has no edema and his lungs are clear. BP 118/72 mmHg, sinus rhythm 78/min, potassium 4.4 mEq/L, eGFR 55 mL/min/1.73 m². Which pharmacologic strategy is most appropriate?
- ATitrate a beta-blocker to target dose and keep it stable for 3 months before considering an ACE inhibitor
- BAdd digoxin 0.125 mg daily for symptoms and leave the rest of the regimen unchanged
- CStart all four drug classes - ARNI (or ACE inhibitor), evidence-based beta-blocker, MRA and SGLT2 inhibitor - within a few weeks, starting the first three at low doses and up-titrating
- DAdd diltiazem to slow the heart rate and reduce myocardial oxygen demand
- ESymptoms are mild and he is euvolemic; observe and repeat the echocardiogram in 6 months
Show answer
Answer C
Source 2021 ESC Guidelines for acute and chronic heart failure and 2023 Focused Update; 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure; 2024 ACC Expert Consensus Decision Pathway for Treatment of HFrEF
- HF-002Multiple choiceCardiologyIntermediate
A 67-year-old woman with HFrEF (LVEF 32%) has tolerated enalapril 10 mg twice daily for years. BP 124/76 mmHg, potassium 4.6 mEq/L, eGFR 62 mL/min/1.73 m², normal liver function. Today you decide to switch her to sacubitril/valsartan. According to the US prescribing information, which switching regimen is correct?
- AStop enalapril, wait 36 hours, then start 24/26 mg twice daily
- BHalve the enalapril dose and overlap with sacubitril/valsartan 24/26 mg twice daily for 1 week, then stop enalapril
- CStop enalapril, wait 12 hours, then start 49/51 mg twice daily
- DStop enalapril, wait 36 hours, then start 49/51 mg twice daily
- EStop enalapril and start 97/103 mg twice daily the next day
Show answer
Answer D
Source Entresto (sacubitril/valsartan) US prescribing information (FDA); 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
- HF-003Multiple choiceCardiologyIntermediate
A 70-year-old man with HFrEF (LVEF 28%) on sacubitril/valsartan, bisoprolol and dapagliflozin was started on spironolactone 25 mg daily 4 weeks ago. Today: potassium 5.7 mEq/L, creatinine 1.45 mg/dL (baseline 1.27 mg/dL), eGFR 47 mL/min/1.73 m², no ECG changes of hyperkalemia, clinically stable. Following the ESC practical guidance, what is the most appropriate action for the spironolactone?
- AContinue the same dose and recheck in 3 months
- BHalve the dose (e.g., 25 mg every other day or 12.5 mg daily) and recheck potassium and renal function within 1 week
- CStop spironolactone immediately and also stop sacubitril/valsartan and dapagliflozin
- DSwitch to eplerenone 50 mg daily, which avoids hyperkalemia
- EStop spironolactone permanently and never retry any MRA
Show answer
Answer B
Source 2021 ESC Guidelines for acute and chronic heart failure (practical guidance on MRA use)
- HF-004Multiple choiceCardiologyAdvanced
A 70-year-old man has newly diagnosed HFrEF (LVEF 25%), NYHA class III, with bilateral leg edema, already being diuresed with IV furosemide. He has never taken other HF medications. BP 96/58 mmHg, sinus rhythm 54/min, potassium 5.3 mEq/L, eGFR 26 mL/min/1.73 m² (stable over 3 months). Which of the following can be safely started now at its usual dose?
- ASpironolactone 25 mg daily
- BSacubitril/valsartan 49/51 mg twice daily
- CCarvedilol 12.5 mg twice daily
- DEmpagliflozin 10 mg daily
- EIvabradine 5 mg twice daily
Show answer
Answer D
Source 2021 ESC Guidelines for acute and chronic heart failure and 2023 Focused Update; 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure; Jardiance (empagliflozin), Entresto (sacubitril/valsartan) and spironolactone US prescribing information
- HF-005Multiple choiceCardiologyIntermediate
A 76-year-old woman with hypertension, obesity (BMI 33 kg/m²) and type 2 diabetes has been hospitalized twice for heart failure in the past year. Echocardiography: LVEF 58%, enlarged left atrium, E/e' 16. NT-proBNP 1250 pg/mL, eGFR 45 mL/min/1.73 m². Congestion is controlled with a diuretic. Per the 2023 ESC focused update, which drug carries a Class I recommendation to reduce HF hospitalization or cardiovascular death?
- ASacubitril/valsartan
- BSpironolactone
- CDigoxin
- DAn SGLT2 inhibitor
- EIvabradine
Show answer
Answer D
Source 2023 Focused Update of the 2021 ESC Guidelines for acute and chronic heart failure (EMPEROR-Preserved, DELIVER)
- HF-006Multiple choiceCardiologyAdvanced
A 68-year-old man is admitted with acutely decompensated chronic heart failure; his home dose is oral furosemide 40 mg daily. BP 136/80 mmHg, warm extremities, crackles over both lower lung fields, severe pitting leg edema. He received furosemide 80 mg IV on arrival. A spot urine sodium at 2 hours is 38 mEq/L, and the 6-hour urine output is 420 mL. Following the ESC algorithm, what is the best next step?
- AContinue the same dose and reassess at 24 hours
- BSwitch to oral torsemide and plan discharge
- CDouble the IV loop diuretic dose and reassess urine sodium and output
- DAdd dobutamine to increase renal perfusion
- EStart ultrafiltration immediately
Show answer
Answer C
Source 2021 ESC Guidelines for acute and chronic heart failure (diuretic algorithm in acute HF); 2019 HFA position statement on diuretics in heart failure with congestion
- HF-010Multiple choiceCardiologyIntermediate
An 80-year-old woman (she just turned 80) has nonvalvular AF with a CHA₂DS₂-VASc score of 5. Weight 62 kg, serum creatinine 1.6 mg/dL, no interacting drugs. What is the correct apixaban dose?
- A5 mg twice daily
- B2.5 mg twice daily
- C2.5 mg once daily
- D5 mg once daily
- EApixaban is contraindicated because of renal impairment
Show answer
Answer B
Source Eliquis (apixaban) US prescribing information (dose adjustment in nonvalvular AF)
- HF-011Multiple choiceCardiologyAdvanced
A 76-year-old man with nonvalvular AF is to start rivaroxaban for stroke prevention. Weight 70 kg, serum creatinine 1.70 mg/dL. After estimating creatinine clearance with the Cockcroft-Gault equation, which dose should be chosen?
- A15 mg once daily with the evening meal
- B20 mg once daily with the evening meal
- C10 mg once daily without regard to food
- D2.5 mg twice daily
- ERivaroxaban is contraindicated when CrCl is <50 mL/min
Show answer
Answer A
Source Xarelto (rivaroxaban) US prescribing information (dosing by Cockcroft-Gault creatinine clearance)
- HF-012Multiple choiceCardiologyIntermediate
A 59-year-old woman had a mechanical mitral valve replacement 8 years ago and has new-onset atrial fibrillation. Renal function is normal and she has no history of bleeding. Per the 2020 ACC/AHA valvular heart disease guideline, her anticoagulation should be:
- ADabigatran 150 mg twice daily
- BRivaroxaban 20 mg once daily
- CWarfarin, INR goal 2.0-3.0
- DWarfarin, INR goal 3.0 (range 2.5-3.5)
- EApixaban 5 mg twice daily
Show answer
Answer D
Source 2020 ACC/AHA Guideline for the Management of Valvular Heart Disease; 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation
- HF-013Multiple choiceCardiologyAdvanced
A 70-year-old man with nonvalvular AF on long-term apixaban 5 mg twice daily (82 kg, serum creatinine 1.0 mg/dL) has an NSTEMI treated with a drug-eluting stent in the LAD. His bleeding risk is not high and he has no high-risk features for stent thrombosis. Which antithrombotic regimen after discharge is most appropriate?
- AApixaban + aspirin + clopidogrel for 6 months, then apixaban + clopidogrel to 12 months
- BApixaban + aspirin + ticagrelor for 12 months
- CTriple therapy only peri-PCI (up to 1 week), then apixaban + clopidogrel to 12 months, then apixaban alone
- DStop apixaban; aspirin + ticagrelor for 12 months
- EReduce apixaban to 2.5 mg twice daily and continue with clopidogrel indefinitely
Show answer
Answer C
Source 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes; 2023 ESC Guidelines for the management of acute coronary syndromes; 2024 ESC Guidelines for the management of atrial fibrillation; 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation
- HF-014Multiple choiceCardiologyBasic
A 58-year-old man has had palpitations that began 5 days ago. ECG shows atrial fibrillation with a ventricular rate of 96/min; BP 132/80 mmHg, no chest pain and no heart failure. He has not been anticoagulated and wants to restore sinus rhythm. What is the correct approach?
- AImmediate synchronized cardioversion; anticoagulation is not needed
- BIV amiodarone pharmacologic cardioversion; anticoagulation is not needed for drug cardioversion
- CEnoxaparin for 24 hours, then electrical cardioversion without TEE
- DCardiovert first, then decide on anticoagulation using the stroke-risk score
- EAnticoagulate for at least 3 weeks (or start anticoagulation and exclude thrombus by TEE) before cardioversion, and for at least 4 weeks after
Show answer
Answer E
Source 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation; 2024 ESC Guidelines for the management of atrial fibrillation
- HF-016Multiple choiceCardiologyAdvanced
A 72-year-old man with hypertension and type 2 diabetes takes apixaban 5 mg twice daily for AF (CrCl 65 mL/min, CHA₂DS₂-VASc 3, no prior stroke). He is scheduled for elective total hip arthroplasty (high bleeding risk) under neuraxial anesthesia on Monday morning. What is the most appropriate perioperative anticoagulation plan?
- AStop apixaban 5 days before surgery and bridge with low-molecular-weight heparin
- BLast dose on the morning before surgery (about 24 hours off)
- CLast dose on Friday morning (about 72 hours off), no heparin bridging
- DContinue apixaban without interruption
- ESwitch to warfarin 1 week before surgery and operate when INR <1.5
Show answer
Answer C
Source ASRA Pain Medicine guidelines on regional anesthesia in patients on antithrombotic therapy (5th edition, 2025); 2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery; 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery; PAUSE trial (JAMA Intern Med 2019)
- HF-017Multiple choiceCardiologyIntermediate
A 26-year-old man has had sudden palpitations for 1 hour. ECG: a grossly irregular wide-QRS tachycardia at about 230/min, with QRS morphology and width varying beat to beat and a delta wave visible at the onset of some complexes. BP 112/70 mmHg, alert. Which management is most appropriate?
- ASynchronized DC cardioversion
- BVerapamil 5 mg IV
- CAdenosine 6 mg rapid IV push
- DDigoxin 0.5 mg IV
- EIV esmolol
Show answer
Answer A
Source 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia; 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation
- HF-018Multiple choiceCardiologyIntermediate
A 47-year-old woman has hypertrophic cardiomyopathy (septum 22 mm, no outflow obstruction) and no hypertension, diabetes, vascular disease or prior stroke. She reports episodic palpitations; paroxysmal AF is documented on a 12-lead ECG during symptoms, and ambulatory monitoring shows episodes lasting up to 3 hours. LVEF 65%, left atrial diameter 44 mm. Regarding stroke prevention, which is correct?
- AHer CHA₂DS₂-VA score is 0, so no antithrombotic therapy is needed
- BAnticoagulate only once the left atrial diameter reaches 45 mm
- CAspirin 81 mg daily is sufficient
- DAF burden is under 24 hours, so defer anticoagulation and keep monitoring
- EOral anticoagulation is recommended regardless of the risk score (DOAC preferred)
Show answer
Answer E
Source 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy; 2024 ESC Guidelines for the management of atrial fibrillation
- HF-019Multiple choiceCardiologyAdvanced
A 55-year-old man has had persistent AF for about 8 months, with worsening dyspnea over the last 3 months. Echocardiography: LVEF 30%, mildly dilated LV; coronary angiography is normal and there is no family history of cardiomyopathy. He is anticoagulated with apixaban. On metoprolol succinate 100 mg daily his resting ventricular rate is still 105-115/min. What is the most appropriate management strategy?
- AAdd dronedarone to maintain sinus rhythm
- BAdd flecainide to maintain sinus rhythm
- CAV-node ablation with biventricular pacing as first choice
- DAdd digoxin and accept permanent AF
- ECatheter ablation to restore sinus rhythm
Show answer
Answer E
Source 2024 ESC Guidelines for the management of atrial fibrillation; 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation
- HF-021Short answerCardiologyIntermediate
A 65-year-old man has newly diagnosed dilated cardiomyopathy, LVEF 28%, NYHA class II-III, mild leg edema. BP 112/70 mmHg, sinus rhythm 88/min, potassium 4.6 mEq/L, eGFR 48 mL/min/1.73 m², no diabetes. Write his discharge medication regimen (drugs and starting doses) and what to monitor 1-2 weeks after starting.
Rubric
- +2Uses a loop diuretic for congestion and adjusts to volume status
- +2Includes an ARNI (sacubitril/valsartan 24/26 mg twice daily) or a low-dose ACE inhibitor (ARB only if intolerant)
- +2Includes an evidence-based beta-blocker (metoprolol succinate, carvedilol or bisoprolol) at low dose with up-titration
- +2Includes an MRA at low dose (spironolactone 12.5 mg daily or 25 mg every other day at eGFR 48) and states the K <5.0 mEq/L and eGFR >30 prerequisites
- +2Includes an SGLT2 inhibitor (dapagliflozin or empagliflozin 10 mg daily)
- +2Rechecks potassium, creatinine, BP and heart rate within 1-2 weeks
- -3Insists on titrating one drug to target dose before starting the next class
- -3Uses diltiazem or verapamil, or prescribes an ACE inhibitor together with sacubitril/valsartan
Show answer
Reference answer Use a loop diuretic for congestion (e.g., furosemide 20-40 mg daily), then reduce to the lowest dose that keeps him euvolemic. Start all four disease-modifying classes within weeks rather than waiting for each to reach target: (1) ARNI sacubitril/valsartan 24/26 mg twice daily (ACE-inhibitor/ARB naive with modest BP; eGFR 30-60 alone does not require a lower dose), or an ACE inhibitor such as enalapril 2.5 mg twice daily or lisinopril 2.5-5 mg daily; (2) an evidence-based beta-blocker at low dose - metoprolol succinate 12.5-25 mg daily, carvedilol 3.125 mg twice daily or bisoprolol 1.25 mg daily - up-titrated about every 2 weeks; (3) MRA spironolactone 12.5 mg daily (eGFR 30-49: 12.5 mg daily or 25 mg every other day; only if K <5.0 mEq/L and eGFR >30); (4) SGLT2 inhibitor dapagliflozin or empagliflozin 10 mg daily, regardless of diabetes. Recheck potassium, creatinine, BP, heart rate and weight 1-2 weeks after each start or dose increase. A creatinine rise of up to 50% (staying below about 3.0 mg/dL) is acceptable; halve the MRA if K >5.5 and stop it if K >6.0. Avoid non-dihydropyridine calcium channel blockers, NSAIDs and thiazolidinediones.
Source 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure; 2021 ESC Guidelines for acute and chronic heart failure and 2023 Focused Update
- HF-022Short answerCardiologyIntermediate
A 70-year-old woman with ischemic cardiomyopathy (LVEF 25%) presents with dyspnea and palpitations for 6 hours. ECG: atrial fibrillation at 150/min. BP 82/50 mmHg, cold clammy skin, apathetic, lactate 4.2 mmol/L, crackles in both lungs. AF duration is unknown and she is not anticoagulated. Outline the emergency management.
Rubric
- +3Recognizes hemodynamic instability and performs immediate synchronized DC cardioversion
- +2States that cardioversion is not delayed for lack of anticoagulation or unknown duration, and gives IV unfractionated heparin as soon as possible without delaying it
- +2Uses IV amiodarone (with or without digoxin) if cardioversion fails or AF recurs
- +1Anticoagulates for at least 4 weeks after cardioversion and long term based on the stroke-risk score (≥2 here)
- +1Supports perfusion (vasopressor/inotrope, ventilatory support)
- +1Looks for ACS and other triggers and corrects potassium and magnesium
- -3Uses diltiazem or verapamil, or gives IV beta-blocker boluses for rate control while hypotensive
- -2Anticoagulates for 3 weeks or waits for a TEE before cardioversion
Show answer
Reference answer This is AF with rapid ventricular response causing hemodynamic instability (hypotension, hypoperfusion). Perform immediate synchronized DC cardioversion under brief, hemodynamically sparing sedation (e.g., etomidate or low-dose ketamine); do not delay it because she is not anticoagulated or because the duration is unknown. Without delaying cardioversion, give IV unfractionated heparin as soon as possible (subcutaneous LMWH absorption is unreliable in shock); continue anticoagulation for at least 4 weeks afterward, and long term because her stroke-risk score is ≥2. With a biphasic device, a high or maximal energy improves first-shock success. If cardioversion fails or AF recurs, use IV amiodarone for rhythm or rate control; digoxin can help with rate. Avoid diltiazem and verapamil, and do not give IV beta-blocker boluses while hypotensive. Support perfusion at the same time: monitoring, oxygen/ventilatory support, norepinephrine and inotropes as needed (dobutamine may accelerate the ventricular rate). Look for triggers: troponin and ECG, urgent coronary angiography if ACS is suspected; infection; correct potassium and magnesium.
Source 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation; 2024 ESC Guidelines for the management of atrial fibrillation; 2021 ESC Guidelines for acute and chronic heart failure
- HF-023Short answerCardiologyAdvanced
A 79-year-old man with AF takes rivaroxaban 20 mg daily; his last dose was about 5 hours ago. He has had hematemesis and melena for 1 day. BP 84/52 mmHg, heart rate 118/min, hemoglobin 6.8 g/dL, CrCl 52 mL/min. Describe the management of the bleeding and the anticoagulation.
Rubric
- +1Stops rivaroxaban immediately
- +1Estimates residual anticoagulant effect from the last-dose time and renal function (anti-Xa activity if available)
- +2Resuscitates with fluids and red cells and gives a reasonable transfusion threshold
- +3Uses andexanet alfa or 4F-PCC (50 units/kg or 2000 units) for life-threatening bleeding; either earns credit
- +2Urgent endoscopy within 24 hours (with IV PPI)
- +2Plans to resume anticoagulation after hemostasis rather than stopping it permanently
- -3Uses vitamin K, protamine or idarucizumab to reverse rivaroxaban
- -2Relies on fresh frozen plasma as the main reversal strategy
Show answer
Reference answer This is a major, life-threatening bleed with shock. (1) Stop rivaroxaban; confirm the time and dose of the last dose; check renal function, coagulation tests (anti-Xa activity if available) and CBC. (2) Large-bore IV access, fluid resuscitation and red cell transfusion (for upper GI bleeding a threshold of about 7-8 g/dL, higher with active coronary disease). (3) For life-threatening bleeding give a reversal agent: four-factor prothrombin complex concentrate (4F-PCC, 50 units/kg or a fixed 2000 units), or andexanet alfa where it is still available (high-dose regimen because the dose was rivaroxaban >10 mg taken <8 hours ago; note the higher thrombotic event rate in ANNEXA-I and limited availability). Guidelines differ here: the 2020 ACC decision pathway supports reversal for life-threatening bleeding with shock, as here, whereas the 2022 ACG-CAG guideline suggests against routine PCC or andexanet in GI bleeding. Tranexamic acid is not recommended for GI bleeding (HALT-IT). Oral activated charcoal is not appropriate with active hematemesis and shock. (4) Urgent endoscopy within 24 hours once resuscitated, with an IV proton pump inhibitor. (5) Vitamin K, protamine and idarucizumab do not reverse rivaroxaban, and fresh frozen plasma is not an effective reversal agent. (6) After hemostasis, reassess and resume anticoagulation (usually within days to 1-2 weeks) in a patient with high stroke risk while treating the bleeding source; do not stop anticoagulation permanently by default.
Source 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants; 2022 ACG-CAG Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding; 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation; 2024 ESC Guidelines for the management of atrial fibrillation
- HF-024Short answerCardiologyIntermediate
A 72-year-old woman with HFrEF takes sacubitril/valsartan 97/103 mg twice daily, spironolactone 25 mg daily, metoprolol succinate 100 mg daily and dapagliflozin 10 mg daily. After 3 days of diarrhea she feels weak. BP 104/62 mmHg, heart rate 58/min, glucose 112 mg/dL. Potassium 6.6 mEq/L, creatinine 2.4 mg/dL (baseline 1.4 mg/dL); ECG shows peaked T waves and mild QRS widening. Describe the emergency treatment and the subsequent adjustment of her HF medications.
Rubric
- +3Gives IV calcium immediately to stabilize the myocardium
- +2Insulin with dextrose to shift potassium (beta-2 agonist optional)
- +2Removes potassium: loop diuretic, potassium binder, dialysis if needed
- +2Stops spironolactone, holds the ARNI and corrects volume depletion
- +2Restarts RAAS inhibitor/MRA at low dose after recovery, possibly with a potassium binder, with close monitoring
- -3Uses sodium bicarbonate or a diuretic instead of calcium as the first measure
- -2Permanently stops all RAAS inhibitors and MRAs
Show answer
Reference answer Hyperkalemia with ECG changes is an emergency. (1) IV calcium immediately to stabilize the myocardium - calcium gluconate 10% (10-30 mL, i.e., 1-3 g, over several minutes) or calcium chloride via a central line; repeat if the ECG does not improve. (2) Shift potassium into cells: regular insulin 10 units IV (5 units, or more dextrose, in older patients or reduced renal function) with 25 g dextrose (50 mL of D50, or a D10 regimen as the UKKA prefers), monitoring glucose hourly for at least 6 hours; nebulized albuterol 10-20 mg can be added. (3) Remove potassium: a loop diuretic once volume is restored, sodium zirconium cyclosilicate (faster onset; patiromer is slower and better for maintenance), and dialysis for refractory hyperkalemia or oliguric AKI. (4) Cardiac monitoring and repeat potassium in 1-2 hours. Medication changes: stop spironolactone and hold sacubitril/valsartan; diarrhea has caused volume depletion and AKI, so give fluids, and the SGLT2 inhibitor can be held during the acute illness. Once renal function and potassium recover, restart the ARNI at a low dose (24/26 mg twice daily), then consider reintroducing the MRA only when K <5.0 mEq/L and eGFR >30, with a potassium binder if needed and close monitoring. The beta-blocker can usually continue, reduced if hypotension or bradycardia develops.
Source UK Kidney Association Clinical Practice Guideline: Treatment of Acute Hyperkalaemia in Adults (2023); 2021 ESC Guidelines for acute and chronic heart failure; 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
- HF-025Short answerCardiologyAdvanced
A 61-year-old man with HFrEF (LVEF 30%) has been in hospital for 6 days with acute decompensation; congestion has resolved after diuresis with 5 kg weight loss. Before discharge: BP 114/72 mmHg, heart rate 84/min, potassium 4.5 mEq/L, eGFR 58 mL/min/1.73 m². Current medications: furosemide 40 mg daily, metoprolol succinate 25 mg daily. Write his medication optimization and follow-up plan around discharge.
Rubric
- +2Starts an SGLT2 inhibitor before discharge
- +2Starts a low-dose ARNI (or ACE inhibitor/ARB) and an MRA before discharge or within 1-2 weeks after (1 point each)
- +2First follow-up within 1-2 weeks of discharge
- +1Rapid up-titration to target or maximally tolerated doses within about 6 weeks
- +1Checks BP, heart rate, potassium, renal function and NT-proBNP at each visit
- +1Up-titrates metoprolol succinate (heart rate 84/min), ideally starting before discharge
- +1Reassesses LVEF after about 3 months of optimized therapy for ICD/CRT
- -2First follow-up or first up-titration only at 3 months
Show answer
Reference answer Per the 2023 ESC update, use rapid initiation and up-titration during the admission and after discharge (Class I). Before discharge, once stable, start the remaining disease-modifying drugs: an SGLT2 inhibitor (dapagliflozin or empagliflozin 10 mg daily), a low-dose ARNI (or ACE inhibitor/ARB) and an MRA (spironolactone 12.5-25 mg daily); continue and up-titrate the beta-blocker. First follow-up within 1-2 weeks of discharge, then every 1-2 weeks, aiming to reach target or maximally tolerated doses within about 6 weeks. At each visit check symptoms and congestion, BP, heart rate, potassium, renal function and NT-proBNP. Adjust the diuretic to the lowest effective dose by daily weights. Education: weigh daily and seek care for a gain of more than about 2 kg (4-5 lb) in 3 days; avoid NSAIDs. After about 3 months of optimized therapy repeat the echocardiogram to assess ICD/CRT eligibility.
Source 2023 Focused Update of the 2021 ESC Guidelines for acute and chronic heart failure (STRONG-HF); 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
- HF-026Short answerCardiologyIntermediate
A 77-year-old woman has HF with preserved EF (LVEF 60%) and hypertension. She has had palpitations for 2 days; ECG shows atrial fibrillation at 135/min. BP 148/84 mmHg, no hypoperfusion, mild dyspnea, not anticoagulated. Weight 55 kg, serum creatinine 0.9 mg/dL, CrCl 45 mL/min, no bleeding history. Describe rate control and anticoagulation.
Rubric
- +2Chooses a beta-blocker or non-dihydropyridine calcium channel blocker for rate control, with optional digoxin
- +2Gives a lenient rate target (resting <110/min)
- +2Correctly scores stroke risk (CHA₂DS₂-VASc 5 or CHA₂DS₂-VA 4) and recommends oral anticoagulation, DOAC preferred
- +2Gives a correct DOAC dose: apixaban 5 mg twice daily, rivaroxaban 15 mg daily, edoxaban 30 mg daily or dabigatran 150 mg twice daily (110 mg twice daily outside the US)
- +1States that cardioversion requires at least 3 weeks of anticoagulation or TEE first (AF ≥48 hours or uncertain duration, high stroke risk)
- -3Uses aspirin instead of anticoagulation
- -2Uses apixaban 2.5 mg twice daily
Show answer
Reference answer She is hemodynamically stable, so control the rate first: with LVEF >40%, a beta-blocker (e.g., metoprolol) or a non-dihydropyridine calcium channel blocker (diltiazem, verapamil), adding digoxin if needed; IV dosing acutely, then oral. Start with lenient rate control (resting heart rate <110/min) and tighten only if symptoms persist. Anticoagulation: CHA₂DS₂-VASc 5 (HF 1, hypertension 1, age ≥75 2, female 1; CHA₂DS₂-VA 4), so oral anticoagulation is recommended, DOAC preferred. Apixaban: of the three criteria (age ≥80, weight ≤60 kg, creatinine ≥1.5 mg/dL) she meets only weight, so 5 mg twice daily. Alternatives: rivaroxaban 15 mg daily with the evening meal (CrCl 15-50), edoxaban 30 mg daily (CrCl 15-50), or dabigatran 150 mg twice daily (US label for CrCl >30; 110 mg twice daily is an option outside the US). If digoxin is used, give a low dose and monitor levels given her age and renal function. AF of 48 hours or more (or uncertain duration), and with her high stroke risk regardless of duration, means cardioversion would require at least 3 weeks of anticoagulation or TEE first. Also check thyroid function and electrolytes, and treat the hypertension.
Source 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation; 2024 ESC Guidelines for the management of atrial fibrillation (RACE II); apixaban, rivaroxaban, edoxaban and dabigatran US prescribing information
- HF-027Short answerCardiologyBasic
A 63-year-old man is found to have atrial fibrillation for the first time on a routine ECG. He is asymptomatic; BP 150/92 mmHg, BMI 31 kg/m², he snores at night and drinks about 5 standard drinks of liquor per day. Apart from assessing anticoagulation, which tests should be done at the initial evaluation, and which modifiable risk factors should be addressed?
Rubric
- +2Transthoracic echocardiogram (structure, LVEF, valve disease)
- +2Thyroid function tests
- +1Electrolytes and renal/liver function (relevant to anticoagulant choice and dosing)
- +2Addresses BP control and assesses for sleep apnea (1 point each)
- +2Addresses weight loss (target ≥10%)
- +2Addresses reducing or stopping alcohol
- +1Recommends regular physical activity
- -2States that asymptomatic AF needs no evaluation or intervention
Show answer
Reference answer Initial tests: 12-lead ECG to confirm AF; transthoracic echocardiogram (chamber size, LVEF, valve disease - particularly to exclude rheumatic mitral stenosis); thyroid function; CBC, electrolytes (potassium, magnesium), renal and liver function (also needed to choose and dose an anticoagulant); glucose/HbA1c and lipids; a sleep study if obstructive sleep apnea is suspected; ambulatory monitoring if needed to assess rate. Modifiable risk factors: control BP; weight loss (target ≥10% of body weight); reduce or stop alcohol (it increases AF recurrence and bleeding); treat sleep apnea; regular exercise; glycemic control. Weight loss, alcohol reduction and physical activity have trial evidence for reducing AF burden and recurrence, and BP control is a core recommendation; the evidence for sleep apnea treatment is weaker.
Source 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation; 2024 ESC Guidelines for the management of atrial fibrillation
- HF-028Short answerCardiologyBasic
A 74-year-old woman with chronic heart failure that has been stable for 3 years presents with 3 days of markedly worse dyspnea and leg edema. Which precipitants of acute decompensation must be looked for immediately, and how would you assess or confirm each?
Rubric
- +2Acute coronary syndrome, assessed with ECG and serial troponin
- +2Arrhythmia (e.g., rapid AF), assessed with ECG
- +1Hypertensive emergency (markedly raised BP with acute target-organ damage)
- +1Acute pulmonary embolism (clinical probability plus D-dimer, CTPA to confirm)
- +1Infection, especially pneumonia (CBC, procalcitonin, chest x-ray)
- +1Acute mechanical complication, valve problem or tamponade, assessed with echocardiography
- +1Medication nonadherence or new HF-worsening drugs such as NSAIDs (history and medication review)
- +1Lists at least two of: worsening renal function, electrolyte disturbance, anemia, thyroid dysfunction (with the matching blood tests)
Show answer
Reference answer Precipitants that need specific urgent treatment (the ESC CHAMPIT mnemonic): acute coronary syndrome (ECG, serial troponin); hypertensive emergency (BP); arrhythmia such as rapid AF or bradyarrhythmia (ECG, monitoring); acute mechanical causes such as acute mitral regurgitation, ventricular septal rupture or worsening valve disease (echocardiography); acute pulmonary embolism (pretest probability and age-adjusted D-dimer to exclude, CT pulmonary angiography to confirm); infection, especially pneumonia (temperature, CBC and chest x-ray to confirm; procalcitonin as an adjunct); cardiac tamponade (echocardiography). Other common precipitants: nonadherence to medication (stopping diuretics), excess salt and fluid, new NSAIDs, non-dihydropyridine calcium channel blockers (in HFrEF) or thiazolidinediones, worsening renal function, electrolyte disturbance, anemia, thyroid dysfunction and alcohol (renal function, electrolytes, CBC, thyroid tests).
Source 2021 ESC Guidelines for acute and chronic heart failure (precipitants of acute HF, CHAMPIT); 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
- HF-029Multiple choiceCardiologyIntermediate
A 64-year-old man (75 kg) with HFrEF (LVEF 32%) remains NYHA class II-III despite optimized guideline-directed medical therapy. Hemoglobin 13.8 g/dL, serum ferritin 180 ng/mL, transferrin saturation 15%. There is no evidence of GI bleeding. What is the most appropriate management of his iron status?
- ANo treatment: his hemoglobin is normal, so iron status is not relevant
- BOral ferrous sulfate 325 mg three times daily for 3 months
- CIntravenous iron (e.g., ferric carboxymaltose or ferric derisomaltose) to improve symptoms and exercise capacity
- DStart an erythropoiesis-stimulating agent
- EHe is not iron deficient because ferritin is above 100 ng/mL; recheck in 6 months
Show answer
Answer C
Source 2023 Focused Update of the 2021 ESC Guidelines for acute and chronic heart failure (IV iron, Class I for symptoms); 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (IV iron, 2a); IRONOUT HF (JAMA 2017)
- HF-030Multiple choiceCardiologyAdvanced
A 45-year-old man (80 kg) with paroxysmal nonvalvular AF had a TIA last month. He has no other medical history. Serum creatinine 0.8 mg/dL, normal liver function, no interacting drugs. He asks for a once-daily anticoagulant and his insurer prefers edoxaban. According to the US prescribing information, which regimen is most appropriate?
- AEdoxaban 60 mg once daily
- BEdoxaban 30 mg once daily
- CEdoxaban 90 mg once daily
- DApixaban 5 mg twice daily
- EAspirin 81 mg plus clopidogrel 75 mg daily
Show answer
Answer D
Source Savaysa (edoxaban) US prescribing information (boxed warning: reduced efficacy in nonvalvular AF with CrCl >95 mL/min); Eliquis (apixaban) US prescribing information
- HF-031Multiple choiceCardiologyAdvanced
A 78-year-old woman (58 kg) with nonvalvular AF takes dronedarone 400 mg twice daily for rhythm control. Serum creatinine 1.1 mg/dL. Her cardiologist wants to start dabigatran. Using the Cockcroft-Gault equation with actual body weight and the US prescribing information, which dose is correct?
- A150 mg twice daily
- B110 mg twice daily
- C75 mg twice daily
- D75 mg once daily
- EDabigatran must not be used because her CrCl is below 30 mL/min
Show answer
Answer C
Source Pradaxa (dabigatran etexilate) US prescribing information (dose adjustment for renal function and P-gp inhibitors in nonvalvular AF)
- HF-032Multiple choiceCardiologyAdvanced
A 59-year-old man had an anterior STEMI treated with primary PCI to the proximal LAD 6 weeks ago. He has taken sacubitril/valsartan, metoprolol succinate, spironolactone and dapagliflozin at tolerated doses since discharge. He is NYHA class II, in sinus rhythm with a QRS duration of 98 ms, and has had no syncope or sustained ventricular arrhythmia. Repeat echocardiography today shows LVEF 30%. What is the most appropriate plan regarding sudden-death prevention?
- AImplant a primary-prevention ICD now, because more than 40 days have passed since the MI
- BImplant a CRT-D device now
- CContinue GDMT and reassess LVEF at least 90 days after revascularization before deciding on an ICD
- DNo ICD is ever indicated because he is only NYHA class II
- EStart amiodarone as an alternative to an ICD
Show answer
Answer C
Source 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (primary-prevention ICD timing); 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure; 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes (post-MI LVEF reassessment)
- HF-033Multiple choiceCardiologyAdvanced
An 82-year-old woman (57 kg) with nonvalvular AF takes apixaban 2.5 mg twice daily; serum creatinine 1.0 mg/dL. She is diagnosed with pulmonary blastomycosis and itraconazole is planned for several months. According to the US prescribing information, what should be done with her anticoagulation?
- AIncrease apixaban to 5 mg twice daily because she has only two dose-reduction criteria
- BContinue apixaban 2.5 mg twice daily unchanged
- CReduce apixaban to 2.5 mg once daily
- DAvoid coadministering apixaban with itraconazole; choose an alternative anticoagulant or antifungal strategy, with interaction monitoring
- EContinue apixaban 2.5 mg twice daily and add aspirin
Show answer
Answer D
Source Eliquis (apixaban) US prescribing information (dose adjustment in nonvalvular AF; combined P-gp and strong CYP3A4 inhibitors)